Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: Secondary analysis of SAILS-ALTOS trial

Mohamed D. Hashem, Ramona O. Hopkins, Elizabeth Colantuoni, Victor D. Dinglas, Pratik Sinha, Lisa Aronson Friedman, Peter E. Morris, James C. Jackson, Catherine L. Hough, Carolyn S. Calfee, Dale M. Needham

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Background Prior acute respiratory distress syndrome (ARDS) trials have identified hypoinflammatory and hyperinflammatory subphenotypes, with distinct differences in short-term outcomes. It is unknown if such differences extend beyond 90 days or are associated with physical, mental health or cognitive outcomes. Methods 568 patients in the multicentre Statins for Acutely Injured Lungs from Sepsis trial of rosuvastatin versus placebo were included and assigned a subphenotype. Among 6-month and 12-month survivors (N=232 and 219, respectively, representing 243 unique survivors), subphenotype status was evaluated for association with a range of patient-reported outcomes (eg, mental health symptoms, quality of life). Patient subsets also were evaluated with performance-based tests of physical function (eg, 6 min walk test) and cognition. Findings The hyperinflammatory versus hypoinflammatory subphenotype had lower overall 12-month cumulative survival (58% vs 72%, p<0.01); however, there was no significant difference in survival beyond 90 days (86% vs 89%, p=0.70). Most survivors had impairment across the range of outcomes, with little difference between subphenotypes at 6-month and 12-month assessments. For instance, at 6 months, in comparing the hypoinflammatory versus hyperinflammatory subphenotypes, respectively, the median (IQR) patient-reported SF-36 mental health domain score was 47 (33-56) vs 44 (35-56) (p=0.99), and the per cent predicted 6 min walk distance was 66% (48%, 80%) vs 66% (49%, 79%) (p=0.76). Interpretation Comparing the hyperinflammatory versus hypoinflammatory ARDS subphenotype, there was no significant difference in survival beyond 90 days and no consistent findings of important differences in 6-month or 12-month physical, cognitive and mental health outcomes. These findings, when considered with prior results, suggest that inflammatory subphenotypes largely reflect the acute phase of illness and its short-term impact.

Original languageEnglish (US)
Pages (from-to)22-30
Number of pages9
JournalThorax
Volume77
Issue number1
DOIs
StatePublished - Jan 1 2022

Keywords

  • ARDS
  • critical care

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Six-month and 12-month patient outcomes based on inflammatory subphenotypes in sepsis-associated ARDS: Secondary analysis of SAILS-ALTOS trial'. Together they form a unique fingerprint.

Cite this